Fulcrum Therapeutics Inc (FULC)
3.26
+0.05
(+1.56%)
USD |
NASDAQ |
Nov 04, 16:00
3.265
0.00 (0.00%)
After-Hours: 20:00
Fulcrum Therapeutics Profit Margin (Quarterly): 69.26% for June 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 69.26% |
| March 31, 2024 | |
| December 31, 2023 | -2.84K% |
| September 30, 2023 | -3.16K% |
| June 30, 2023 | -2.70K% |
| March 31, 2023 | -8.40K% |
| December 31, 2022 | -3.82K% |
| September 30, 2022 | -2.01K% |
| June 30, 2022 | -1.81K% |
| Date | Value |
|---|---|
| March 31, 2022 | -1.00K% |
| December 31, 2021 | -464.3% |
| September 30, 2021 | -419.8% |
| June 30, 2021 | -448.5% |
| March 31, 2021 | -355.0% |
| December 31, 2020 | -419.4% |
| September 30, 2020 | -1.03K% |
| June 30, 2020 | -784.2% |
| March 31, 2020 | -2.46K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-8.40K%
Minimum
Mar 2023
69.26%
Maximum
Jun 2024
-1.89K%
Average
-1.03K%
Median
Sep 2020
Profit Margin (Quarterly) Benchmarks
| Bioventus Inc | -15.87% |
| Arcturus Therapeutics Holdings Inc | -37.45% |
| Entrada Therapeutics Inc | 58.11% |
| Johnson & Johnson | 11.99% |
| Insmed Inc | -236.0% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -8.07% |
| Return on Assets | -7.42% |
| Return on Invested Capital | -8.07% |
| Operating Margin (Quarterly) | 65.62% |
| Return on Net Operating Assets | -113.0% |